Open Access

Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation

  • Authors:
    • Liang Liang
    • Dan‑Ming Wei
    • Jian‑Jun Li
    • Dian‑Zhong Luo
    • Gang Chen
    • Yi‑Wu Dang
    • Xiao‑Yong Cai
  • View Affiliations

  • Published online on: November 3, 2017     https://doi.org/10.3892/mmr.2017.7945
  • Pages: 939-951
  • Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Although certain biomarkers that are directly associated with the overall survival (OS) of patients with pancreatic adenocarcinoma (PAAD) have been identified, the efficacy of a single factor is limited to predicting the prognosis. The aim of the present study was to identify a combination micro (mi)RNA signature that enhanced the prognostic prediction for PAAD. Following analysis of the data available from The Cancer Genome Atlas (TCGA), 175 PAAD samples were selected for the present study, and the associations between 494 miRNAs and OS were investigated. The prognostic value of all miRNAs was analyzed by multivariate Cox regression, and the miRNAs were ranked according to the hazard ratio (HR) and P‑values. The top 5 miRNAs (miR‑1301, miR‑125a, miR‑376c, miR‑328 and miR‑376b) were significantly associated with OS (HR=0.139; 95% confidence interval, 0.043‑0.443; P<0.001), thus demonstrating that this panel was able to serve as an independent prognostic factor for PAAD. In addition, the present study also predicted the target genes of the top 10 miRNAs with the highest prognostic values using 12 different prediction software, and enrichment signaling pathway analyses elucidated that several pathways may be markedly associated with these miRNAs, including ‘Pathways in cancer’, ‘Chronic myeloid leukemia’, ‘Glioma’ and ‘MicroRNAs in cancer’. Lastly, ubiquitin C, epidermal growth factor receptor, estrogen receptor 1, mitogen‑activated protein kinase 1, mothers against decapentaplegic homolog 4 and androgen receptor may be the hub genes revealed by STRING analysis. The present study identified several miRNAs, particularly a five‑miRNA‑pool, that may be reliable, independent factors for predicting survival in patients with PAAD. However, the underlying molecular mechanisms require further investigation in the future.

References

1 

Yu J, Ohuchida K, Mizumoto K, Fujita H, Nakata K and Tanaka M: MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol Ther. 10:748–757. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Wang Z, Li J, Chen X, Duan W, Ma Q and Li X: Disrupting the balance between tumor epithelia and stroma is a possible therapeutic approach for pancreatic cancer. Med Sci Monit. 20:2002–2006. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Liang S, Yang Z, Li D, Miao X, Yang L, Zou Q and Yuan Y: The clinical and pathological significance of Nectin-2 and DDX3 expression in pancreatic ductal adenocarcinomas. Dis Markers. 2015:3795682015. View Article : Google Scholar : PubMed/NCBI

4 

Lee SH, Kang CM, Kim H, Hwang HK, Song SY, Seong J, Kim MJ and Lee WJ: Pathological complete remission of pancreatic cancer following neoadjuvant chemoradiation therapy; not the end of battles. Medicine (Baltimore). 94:e21682015. View Article : Google Scholar : PubMed/NCBI

5 

Chen Y, Wang X, Ke N, Mai G and Liu X: Inferior mesenteric vein serves as an alternative guide for transection of the pancreatic body during pancreaticoduodenectomy with concomitant vascular resection: A comparative study evaluating perioperative outcomes. Eur J Med Res. 19:422014. View Article : Google Scholar : PubMed/NCBI

6 

Yang YF, Cao XH, Bao CE and Wan X: Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: A systematic review and meta-analysis. Onco Targets Ther. 8:3315–3322. 2015.PubMed/NCBI

7 

Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Ali S, Dubaybo H, Brand RE and Sarkar FH: Differential expression of MicroRNAs in tissues and plasma co-exists as a biomarker for pancreatic cancer. J Cancer Sci Ther. 7:336–346. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Loosen SH, Neumann UP, Trautwein C, Roderburg C and Luedde T: Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol. 39:10104283176922312017. View Article : Google Scholar : PubMed/NCBI

10 

Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Pillai RS: MicroRNA function: Multiple mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Xiao J, Peng F, Yu C, Wang M, Li X, Li Z, Jiang J and Sun C: microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Int J Clin Exp Pathol. 7:7442–7450. 2014.PubMed/NCBI

13 

Lin MS, Chen WC, Huang JX, Gao HJ and Sheng HH: Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer. Int J Clin Exp Med. 7:5226–5234. 2014.PubMed/NCBI

14 

Kai Y, Qiang C, Xinxin P, Miaomiao Z and Kuailu L: Decreased miR-154 expression and its clinical significance in human colorectal cancer. World J Surg Oncol. 13:1952015. View Article : Google Scholar : PubMed/NCBI

15 

Hou LJ and Zhai JJ: Aberrant expression profile of translationally controlled tumor protein and tumor-suppressive microRNAs in cervical cancer. J BUON. 20:1504–1509. 2015.PubMed/NCBI

16 

Lu Y, Hu J, Sun W, Li S, Deng S and Li M: MiR-29c inhibits cell growth, invasion, and migration of pancreatic cancer by targeting ITGB1. Onco Targets Ther. 9:99–109. 2016.PubMed/NCBI

17 

Dong Q, Li C, Che X, Qu J, Fan Y, Li X, Li Y, Wang Q, Liu Y, Yang X and Qu X: MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Oncotarget. 7:82338–82353. 2016.PubMed/NCBI

18 

Li BS, Liu H and Yang WL: Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis. Genet Mol Res. 14:16372–16378. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, et al: MicroRNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? Oncotarget. 6:23323–23341. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Wang C, Sun Y, Wu H, Yu S, Zhang L, Meng Y, Liu M, Yang H, Liu P, Mao X, et al: Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol. 36:9447–9456. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Bai Z, Sun J, Wang X, Wang H, Pei H and Zhang Z: MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma. Oncol Rep. 34:595–602. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Shi H, Chen J, Li Y, Li G, Zhong R, Du D, Meng R, Kong W and Lu M: Identification of a six microRNA signature as a novel potential prognostic biomarker in patients with head and neck squamous cell carcinoma. Oncotarget. 7:21579–21590. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Wang M, Wen TF, He LH, Li C, Zhu WJ and Trishul NM: A six-microRNA set as prognostic indicators for bile duct cancer. Int J Clin Exp Med. 8:17261–17270. 2015.PubMed/NCBI

24 

Zheng H, Guo X, Tian Q, Li H and Zhu Y: Distinct role of Tim-3 in systemic lupus erythematosus and clear cell renal cell carcinoma. Int J Clin Exp Med. 8:7029–7038. 2015.PubMed/NCBI

25 

Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods. 12:6972015. View Article : Google Scholar : PubMed/NCBI

26 

Kanehisa M, Furumichi M, Tanabe M, Sato Y and Morishima K: KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Zhang SW, Wang J and Pan J: Identification of altered pathways in hypertrophic cardiomyopathy based on combined data of protein-protein interactions and molecular pathways. Genet Mol Res. 15:2016.

28 

Jiang M, Zeng Q, Dai S, Liang H, Dai F, Xie X, Lu K and Gao C: Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles. Mol Med Rep. 15:380–386. 2017. View Article : Google Scholar : PubMed/NCBI

29 

Gu Y, Lu L, Wu L, Chen H, Zhu W and He Y: Identification of prognostic genes in kidney renal clear cell carcinoma by RNA-seq data analysis. Mol Med Rep. 15:1661–1667. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al: Towards a knowledge-based human protein atlas. Nat Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI

32 

Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW and Peng CH: Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: Meta-analysis, experimental validation and clinical significance. J Exp Clin Cancer Res. 32:712013. View Article : Google Scholar : PubMed/NCBI

33 

Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, et al: microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Eur J Cancer. 51:1389–1404. 2015. View Article : Google Scholar : PubMed/NCBI

34 

Cheng PF, Dummer R and Levesque MP: Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss Med Wkly. 145:w141832015.PubMed/NCBI

35 

Fang L, Yang N, Ma J, Fu Y and Yang GS: microRNA-1301-mediated inhibition of tumorigenesis. Oncol Rep. 27:929–934. 2012. View Article : Google Scholar : PubMed/NCBI

36 

Lin TY, Chen KC, Liu HJ, Liu AJ, Wang KL and Shih CM: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL nuclear entrapment to enhance imatinib efficacy in chronic myeloid leukemia cells. PLoS One. 11:e01562602016. View Article : Google Scholar : PubMed/NCBI

37 

Bi D, Ning H, Liu S, Que X and Ding K: miR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C. Biomed Pharmacother. 81:25–30. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Zhang Y, Xue C, Zhu X, Zhu X, Xian H and Huang Z: Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation. Cell Signal. 28:850–860. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Li LJ, Huang Q, Zhang N, Wang GB and Liu YH: miR-376b-5p regulates angiogenesis in cerebral ischemia. Mol Med Rep. 10:527–535. 2014.PubMed/NCBI

40 

Xiong H, Li Q, Liu S, Wang F, Xiong Z, Chen J, Chen H, Yang Y, Tan X, Luo Q, et al: Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage I endometrioid endometrial carcinoma. PLoS One. 9:e1101632014. View Article : Google Scholar : PubMed/NCBI

41 

Leidinger P, Brefort T, Backes C, Krapp M, Galata V, Beier M, Kohlhaas J, Huwer H, Meese E and Keller A: High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. Oncotarget. 7:4611–4623. 2016. View Article : Google Scholar : PubMed/NCBI

42 

Mishra S, Srivastava AK, Suman S, Kumar V and Shukla Y: Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Lett. 369:67–75. 2015. View Article : Google Scholar : PubMed/NCBI

43 

Shao N, Wang L, Xue L, Wang R and Lan Q: Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 36:309–313. 2015. View Article : Google Scholar : PubMed/NCBI

44 

Wu X, Ding N, Hu W, He J, Xu S, Pei H, Hua J, Zhou G and Wang J: Down-regulation of BTG1 by miR-454-3p enhances cellular radiosensitivity in renal carcinoma cells. Radiat Oncol. 9:1792014. View Article : Google Scholar : PubMed/NCBI

45 

Zhang JX, Chen ZH, Xu Y, Chen JW, Weng HW, Yun M, Zheng ZS, Chen C, Wu BL, Li EM, et al: Downregulation of MicroRNA-644a promotes esophageal squamous cell carcinoma aggressiveness and stem cell-like phenotype via dysregulation of PITX2. Clin Cancer Res. 23:298–310. 2017. View Article : Google Scholar : PubMed/NCBI

46 

Chen Q, Hu H, Jiao D, Yan J, Xu W, Tang X, Chen J and Wang J: miR-126-3p and miR-451a correlate with clinicopathological features of lung adenocarcinoma: The underlying molecular mechanisms. Oncol Rep. 36:909–917. 2016. View Article : Google Scholar : PubMed/NCBI

47 

Wu XJ, Zhao ZF, Kang XJ, Wang HJ, Zhao J and Pu XM: MicroRNA-126-3p suppresses cell proliferation by targeting PIK3R2 in Kaposi's sarcoma cells. Oncotarget. 7:36614–36621. 2016. View Article : Google Scholar : PubMed/NCBI

48 

Ji H, Chen M, Greening DW, He W, Rai A, Zhang W and Simpson RJ: Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures. PLoS One. 9:e1103142014. View Article : Google Scholar : PubMed/NCBI

49 

Suresh R, Sethi S, Ali S, Giorgadze T and Sarkar FH: Differential expression of microRNAs in papillary thyroid carcinoma and their role in racial disparity. J Cancer Sci Ther. 7:145–154. 2015.PubMed/NCBI

50 

Pullen TJ, da Silva Xavier G, Kelsey G and Rutter GA: miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol Cell Biol. 31:3182–3194. 2011. View Article : Google Scholar : PubMed/NCBI

51 

Sulpizio S, Franceschini N, Piattelli A, Di Sebastiano P, Innocenti P and Selvaggi F: Cathepsins and pancreatic cancer: The 2012 update. Pancreatology. 12:395–401. 2012. View Article : Google Scholar : PubMed/NCBI

52 

Zhou X, Huang Z, Xu L, Zhu M, Zhang L, Zhang H, Wang X, Li H, Zhu W, Shu Y and Liu P: A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget. 7:69616–69624. 2016.PubMed/NCBI

Related Articles

Journal Cover

January 2018
Volume 17 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liang, L., Wei, D., Li, J., Luo, D., Chen, G., Dang, Y., & Cai, X. (2018). Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation. Molecular Medicine Reports, 17, 939-951. https://doi.org/10.3892/mmr.2017.7945
MLA
Liang, L., Wei, D., Li, J., Luo, D., Chen, G., Dang, Y., Cai, X."Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation". Molecular Medicine Reports 17.1 (2018): 939-951.
Chicago
Liang, L., Wei, D., Li, J., Luo, D., Chen, G., Dang, Y., Cai, X."Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation". Molecular Medicine Reports 17, no. 1 (2018): 939-951. https://doi.org/10.3892/mmr.2017.7945